GD2TIF cells as a platform for single-dose and long-term delivery of biologics



Summary

GD2TIF cells, genetically engineered to express therapeutic molecules in response to tumor-specific GD2 disialoganglioside, hold promise for single-dose, long-term biologic delivery. These cells act as “drug factories” within the tumor microenvironment, continuously producing and secreting therapeutic proteins or antibodies, eliminating the need for repeated administrations. The tumor-responsive mechanism ensures targeted delivery, minimizing off-target effects. This approach offers potential advantages over traditional biologic delivery methods, including sustained therapeutic levels, reduced systemic exposure, and improved patient compliance, making it a promising strategy for cancer treatment. Further research is needed to optimize safety and efficacy.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!